Feb 3 (Reuters) - Pfizer said on Tuesday its experimental obesity drug, which it acquired through the Metsera deal, showed up ...

Pfizer reported strong mid-stage weight loss trial results for its monthly obesity drug and posted fourth-quarter earnings ...

Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

Pfizer signaled some promise in its long-running attempt to develop an anti-obesity drug on Tuesday, but analysts say limited results and missing safety information left Wall Street still uncertain ...

Pfizer’s PFE second-quarter 10% revenue growth and adjusted EPS of $0.78 were ahead of consensus expectations. Management maintained full-year revenue guidance of $61 billion-$64 billion and raised ...

Eli Lilly’s Zepbound is still viewed as the leading weight-loss shot, according to a ...

Boltz Bags $28M Funding and Pfizer Partnership for Biomolecular AI Boost Your email has been sent Pfizer and Boltz have announced a collaboration aimed at expanding the use of advanced biomolecular AI ...